TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dbv Technologies
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies released its half-year liquidity report for the period ending December 31, 2025, showing 74,580 shares and €527,891.63 in the liquidity account with ODDO BHF. The company executed 1,658 buy and 1,867 sales transactions, trading approximately 1.5 million shares on purchases and 1.6 million shares on sales. DBV Technologies continues clinical trials of its Viaskin platform for food allergies, with ongoing Phase 3 VITESSE trial results announced in December 2025.

Insights
DBVT   positive

The company announced positive topline results from its Phase 3 VITESSE trial for Viaskin Peanut in December 2025, indicating clinical progress. Active trading volume and maintained liquidity account suggest investor engagement and market activity in the stock.